Bilthoven, April 21, 2016 - An international multi-disciplinary consortium of 11 partners, in which 5 leading academic institutes, 4 cutting - edge biotech companies and 2 excellent service providers will join forces to advance the treatment of cancer using
an innovative immunotherapeutic nanomedicin, has received an $ 8.3 million Horizon 2020 grant (grant agreement No 686089).